Provided by Tiger Fintech (Singapore) Pte. Ltd.

Coherus BioSciences

0.8778
-0.0624-6.64%
Post-market: 0.89000.0122+1.39%19:58 EDT
Volume:1.96M
Turnover:1.74M
Market Cap:101.77M
PE:-0.77
High:0.9537
Open:0.9400
Low:0.8421
Close:0.9402
Loading ...

Positive week for Coherus Oncology, Inc. (NASDAQ:CHRS) institutional investors who lost 47% over the past year

Simply Wall St.
·
14 Jul

Truist Financial Reaffirms Their Buy Rating on Coherus Biosciences (CHRS)

TIPRANKS
·
09 Jul

Coherus Oncology Inc. Receives Nasdaq Deficiency Notice for Falling Below Minimum Bid Price Requirement

Reuters
·
04 Jul

Coherus Oncology Inc. Conducted Annual Stockholders Meeting Virtually

Reuters
·
14 Jun

Coherus Biosciences completes transformation to Coherus Oncology

TIPRANKS
·
30 May

BRIEF-Coherus Completes Strategic Transformation To Coherus Oncology

Reuters
·
30 May

Coherus BioSciences Rebrands as Coherus Oncology, Emphasizing Cancer Therapeutics

Reuters
·
30 May

Maxim Group Sticks to Its Hold Rating for Coherus Biosciences (CHRS)

TIPRANKS
·
30 May

Director Mats Wahlstrom Reports Disposal of Coherus BioSciences Inc. Common Shares

Reuters
·
29 May

Coherus BioSciences Announces Launch of Phase 1b/2 Clinical Trial for LOQTORZI and STC-15 Combination Targeting Various Cancers

Reuters
·
27 May

Coherus BioSciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

Coherus BioSciences Q1 Adj. EPS $(0.35) Up From $(0.48) YoY, Sales $7.60M Up From $2.31M YoY

Benzinga
·
13 May

BRIEF-Coherus BioSciences Q1 Net Income USD -56.569 Million

Reuters
·
13 May

Coherus BioSciences Reports Q1 2025: Net Loss from Continuing Operations Narrows to $47.4M, LOQTORZI Revenue at $7.3M, UDENYCA Discontinued Operations Net Revenue at $31.5M

Reuters
·
13 May

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
12 May

Coherus BioSciences Inc expected to post a loss of 21 cents a share - Earnings Preview

Reuters
·
10 May

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

GlobeNewswire
·
06 May

Coherus BioSciences Inc expected to post a loss of 21 cents a share - Earnings Preview

Reuters
·
05 May

Coherus to Participate in Upcoming Investor Conferences

GlobeNewswire
·
02 May

Coherus BioSciences Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
29 Apr